logo
First artificial solar eclipse from space captured by ESA Proba-3 mission

First artificial solar eclipse from space captured by ESA Proba-3 mission

Yahoo18-06-2025
A satellite duo orbiting our planet has just captured the very first images of an artificial solar eclipse from space, providing us with a spectacular view of the Sun's corona — a view only rarely available to us here on Earth.
Total solar eclipses are amazing to behold. They spark awe and wonder in those fortunate enough to witness the event. Also, the brief moments of totality give us a chance to see and study parts of the Sun that are nearly impossible to observe at any other time.
The April 8 total solar eclipse, imaged from Dallas, Texas, during 'totality', when the Moon completely blocked the Sun. While a few red-tinged prominances are visible along the edge of the Moon, the primary feature we see is the solar corona, which is shaped and sculpted by the Sun's powerful magnetic fields. (NASA/Keegan Barber)
The solar corona is the Sun's atmosphere. It is the source of the solar wind, which constantly flows past our planet and causes auroras to shine near the north and south poles. It also holds one of the biggest mysteries of our solar system, as it reaches temperatures of about 1 million degrees Celsius, while the surface of the Sun (the photosphere) is only around 5,500°C.
There have been clues over the years, but overall, scientists are still trying to find out exactly why the corona is so much hotter than the photosphere.
The main reason for this is that studying the corona is challenging. We can see it during a total solar eclipse, but those are few and far in-between. And even when one does occur, the time they have to observe it — right at totality — only lasts for a few minutes each time. Jets have been able to extend this time a bit, as they fly straight down the path of totality, but the shadow of the Moon moves too quickly to get a sustained look.
Special cameras known as coronagraphs give us longer observations of the corona. Two flying in space right now, one on the NASA/ESA Solar and Heliospheric Observatory (SOHO) and the other on the GOES-19 weather satellite, have a small disk at the end of an arm positioned in front of the camera lens to cover the Sun.
Two composite views of the Sun from SOHO and the Solar Dynamics Observatory show the outer parts of the solar corona. As the innermost part of each image reveals, there is a lot of space between the inner edge of SOHO's coronagraph view and the surface of the Sun, which means we do not get a consistent look at the inner corona. (NASA SDO/NASA-ESA SOHO/Scott Sutherland)
With that disk in place, the sensitive camera can then pick up the much fainter activity going on around the Sun. However, when scientists fly one of these instruments, they have to account for the entire range of distance the satellite will be from the Sun, thus the disk has to give a lot of leeway, to prevent the Sun from peaking around the edge of the coronagraph and burning out the optics. Thus, these coronagraphs can never give us as good a view of the corona as we see during a total solar eclipse, where we can even view the very lowest layers of the Sun's atmosphere.
The European Space Agency's Proba-3 mission solves that problem, though. The two satellites that are part of the mission — the Coronagraph and the Occulter — fly in precise formation, orbiting around the Earth. Each time they come around on the Sun-ward side of the planet, they line up perfectly, at just the right distance, that the Occulter perfectly covers up the Sun's disk, just like the Moon does during a total solar eclipse.
Proba-3's Coronagraph and Occulter fly in tandom as they loop around the sunward side of Earth, with the Occulter at the precise distance to block the Sun's disk for the camera. (ESA)
Now, Proba-3 has sent back its very first artificial solar eclipse images, and the results are pretty amazing.
"Seeing the first data from ASPIICS is incredibly exciting," Joe Zender, Proba-3 project scientist, said in an ESA press release. "Together with the measurements made by another instrument on board, DARA, ASPIICS will contribute to unravelling long-lasting questions about our home star."
The Sun's inner corona is revealed in this image taken by Proba-3's ASPIICS coronagraph, on May 23, 2025. The image shows the corona similar to how the human eye would see it during an eclipse, but through a green filter. The details of the image were enhanced by a specialized image processing algorithm. (ESA)
"Each full image — covering the area from the occulted Sun all the way to the edge of the field of view — is actually constructed from three images," said Andrei Zhukov, the principal investigator for ASPIICS at the Royal Observatory of Belgium. "The difference between those is only the exposure time, which determines how long the coronagraph's aperture is exposed to light. Combining the three images gives us the full view of the corona."
"Our 'artificial eclipse' images are comparable with those taken during a natural eclipse," Zhukov explained. "The difference is that we can create our eclipse once every 19.6-hour orbit, while total solar eclipses only occur naturally around once, very rarely twice a year. On top of that, natural total eclipses only last a few minutes, while Proba-3 can hold its artificial eclipse for up to 6 hours.'
This artist's impression shows the Proba-3 Occulter blocking the Sun's disk so that the Coronagraph can image the space around the Sun. (ESA)
At the moment, Proba-3 is still receiving guidance from ESA operators on the ground, so that the two spacecraft continue to fly in perfect formation. However, the mission team's goal is to get the two doing this precision flying all on their own. Once that happens, they can leave the pair to send back new observations after each orbit.
The data returned by the mission will not only help researchers solve the mysteries of the corona's extreme temperatures, but it will also help space weather scientists, as well. The images returned by Proba-3 can act as an important tool to verify their computer models of the corona, which are used to forecast the impacts of solar activity here on Earth.
Thus, as Proba-3 continues to send back data, this could improve our ability to forecast auroras or even the potential disruptions to satellites and power grids that can result from extreme space weather.
Click here to view the video
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Yahoo

time5 minutes ago

  • Yahoo

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced FDA removal of partial clinical hold on PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis Submitted Type C meeting request to the FDA to meet during the fourth quarter of 2025 to discuss the development plan for zetomipzomib in autoimmune hepatitis PORTOLA Phase 2a data selected for oral presentation at The Liver Meeting® 2025 Cash, cash equivalents and marketable securities totaled $101 million as of June 30, 2025 SOUTH SAN FRANCISCO, Calif., August 13, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We are committed to working closely with the FDA to align on our next trial design, which we have proposed as a registration-enabling study. The Type C meeting will be an important milestone as we continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with autoimmune hepatitis." Zetomipzomib: Selective Immunoproteasome Inhibitor In March, Kezar reported topline results from the PORTOLA Phase 2a clinical trial evaluating zetomipzomib in patients with autoimmune hepatitis (AIH). In relapsed or refractory AIH patients who entered screening on steroid-based therapy, 36% (5 of 14) of zetomipzomib-treated patients achieved a complete biochemical response (CR) and clinically significant steroid taper to 5 mg/day or less by 6 months, compared to 0 of 7 placebo patients. The median duration of response in zetomipzomib patients achieving a CR was 27.6 weeks (including the ongoing open-label extension at the time of the data cutoff), and no disease flares were reported in any zetomipzomib-treated patient achieving CR during study. A favorable safety profile was observed during the 6-month blinded treatment period. In July, Kezar announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) removed the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with AIH. Kezar submitted a Type C meeting request to the FDA to meet during the fourth quarter of 2025 to discuss the AIH development plan for zetomipzomib. Kezar submitted a complete response to the FDA Division of Rheumatology and Transplant Medicine with a request to remove the clinical hold on zetomipzomib in lupus nephritis. Medical Conferences An abstract featuring PORTOLA Phase 2a data has been selected for an oral presentation at The Liver Meeting® 2025, taking place November 7-11, in Washington, DC. An abstract featuring PORTOLA biomarker data has been selected for poster presentation at The Liver Meeting® 2025. Business Updates In June, Zung To was promoted to Chief Development Officer. Mr. To joined Kezar in 2023 as Senior Vice President & Head of Clinical Development and brings 35 years of industry experience, with more than 20 years in senior leadership roles in early-and late-stage clinical development. He has been instrumental in leading Kezar's development strategy and has played a pivotal role in progressing the Company's clinical trials with speed and precision. Financial Results Cash, cash equivalents and marketable securities totaled $100.8 million as of June 30, 2025, compared to $132.2 million as of December 31, 2024. The decrease was primarily attributable to cash used in operations. Research and development (R&D) expenses for the second quarter of 2025 decreased by $6.7 million to $9.6 million, compared to $16.3 million in the second quarter of 2024. This decrease was primarily due to the decreased clinical activities resulting from the completion and closeout of clinical trials, a decrease in personnel costs including non-cash stock-based compensation and a decrease in facility related expenses. General and administrative (G&A) expenses for the second quarter of 2025 decreased by $0.6 million to $5.0 million compared to $5.6 million in the second quarter of 2024. The decrease was primarily due to a decrease in non-cash stock-based compensation and personnel-related expenses. Restructuring and impairment charges for the second quarter of 2025 decreased by $1.5 million, compared to the second quarter of 2024. The decrease was primarily attributed to the impairment charge in 2024 related to the right-of-use asset for the vacated floor in the company's leased office facility. Net loss for the second quarter of 2025 was $13.7 million, or $1.87 per basic and diluted common share, compared to a net loss of $21.5 million, or $2.96 per basic and diluted common share, for the second quarter of 2024. Total shares of common stock outstanding were 7.3 million shares as of June 30, 2025. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, X and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the initiation of a registration-enabling trial of zetomipzomib, the clinical development of and regulatory submission plan for zetomipzomib in AIH, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. KEZAR LIFE SCIENCES, INC. Selected Balance Sheets Data (In thousands) June 30, 2025 December 31, 2024 (unaudited) Cash, cash equivalents and marketable securities $ 100,849 $ 132,245 Total assets 109,123 144,682 Total current liabilities 14,365 20,329 Total noncurrent liabilities 2,972 7,437 Total stockholders' equity 91,786 116,916 Summary of Operations Data (In thousands except share and per share data) Three Months Ended Six Months Ended June 30 June 30 2025 2024 2025 2024 (unaudited) (unaudited) Operating expenses: Research and development $ 9,583 $ 16,298 $ 21,763 $ 33,470 General and administrative 5,016 5,603 10,465 12,142 Restructuring and impairment charges - 1,482 - 1,482 Total operating expenses 14,599 23,383 32,228 47,094 Loss from operations (14,599 ) (23,383 ) (32,228 ) (47,094 ) Interest income 1,197 2,237 2,617 4,690 Interest expense (302 ) (401 ) (649 ) (801 ) Net loss $ (13,704 ) $ (21,547 ) $ (30,260 ) $ (43,205 ) Net loss per common share, basic and diluted $ (1.87 ) $ (2.96 ) $ (4.14 ) $ (5.93 ) Weighted-average shares used to compute net loss per common share, basic and diluted 7,311,032 7,284,587 7,308,360 7,282,289 View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences,

Paramount's ‘Star Trek' Focus Is Back at the Movies—Including ‘Star Trek 4' (Again)
Paramount's ‘Star Trek' Focus Is Back at the Movies—Including ‘Star Trek 4' (Again)

Gizmodo

time7 minutes ago

  • Gizmodo

Paramount's ‘Star Trek' Focus Is Back at the Movies—Including ‘Star Trek 4' (Again)

There's been no shortage of Star Trek for fans in recent years—provided, of course, they subscribe to Paramount+. But as the sci-fi stalwart's number of streaming series has dwindled to just Strange New Worlds (which has an endpoint set after its fifth season) and the upcoming Starfleet Academy, the studio behind the franchise is seemingly ramping up hopes for a big-screen return. If that sounds like a promise you've heard before, you're not wrong. The most recent reboot or Kelvin Timeline (or 'Chris Pine as Captain Kirk,' if you prefer) film came in 2016 with Star Trek Beyond, and there have been many rumblings of new projects in the nearly 10 years since. There was the S.J. Clarkson version with Chris Hemsworth planning a return as Kirk's father. There was the Noah Hawley version. The Matt Shakman version. And the Quentin Tarantino version, which is near-mythical at this point. But with Paramount under the microscope following its high-profile corporate shake-ups (you saw South Park, right?), executives are sifting through the studio's most valuable IP to prioritize plans moving forward. As Deadline reports, an earnings call today saw CEO David Ellison declaring plans to make Paramount 'the number one studio for filmmakers and talent in the world.' That includes increasing the number of movies released annually, with Star Trek 'a high priority.' Ellison, the trade points out, has been tied into Star Trek since 2013's Star Trek Into Darkness, which counted him among its executive producers. 'As for right now,' Deadline writes, 'they are developing a film that includes brand new characters that Andor director Toby Haynes is on board to direct with Seth Grahame Smith writing and Simon Kinberg and J.J. Abrams producing.' This is not news—it's the 'origins of Starfleet' movie that has been percolating since January 2024—though it's a good reminder that we knew this project was in the works. More intriguing, though, is this: 'They also have another installment with Captain Kirk, Spock, and the rest of usual characters returning that also has Abrams producing and Steve Yockey writing.' That can only be Star Trek 4, a movie we've long known is in the works in some capacity, but has kept being shuffled around between directors. (Shakman, the most recently attached, left in 2022 when he was hired to helm The Fantastic Four: First Steps.) Could the studio's renewed push toward big-screen movies mean yet another director announcement is coming soon—and perhaps, hope against hope, an actual movie to follow? Share your speculation and tell Paramount who it should hire to make Star Trek 4 in the comments below. Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what's next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Trump administration ordered to restore some withheld grant funding to UCLA
Trump administration ordered to restore some withheld grant funding to UCLA

Washington Post

time8 minutes ago

  • Washington Post

Trump administration ordered to restore some withheld grant funding to UCLA

A federal judge has ordered the Trump administration to restore millions of dollars in National Science Foundation grants it has withheld from the University of California, Los Angeles, saying they were made in violation of her earlier court ruling. U.S. District Judge Rita F. Lin ruled late Tuesday that the NSF must reinstate the research grants that were suspended for reasons she had already ruled 'arbitrary and capricious,' and gave the administration until Aug. 19 to show compliance or explain why it hasn't restored the money.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store